Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
- Conditions
- Age Related Macular Degeneration
- Registration Number
- NCT00347399
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Brief Summary
The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.
- Detailed Description
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 25
55 years old neovascular Age related acular degeneration subfoveolar neovascular membrane best corrected visual acuity better than 20/200 snellen (1.0 logMAR)
- Previously treated eyes glaucoma diabetes mellitus uncontrolled hypertension coronary artery disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Visual acuity improvement at 6 months undefined undefined
- Secondary Outcome Measures
Name Time Method Retinal thickness improvement at 6 months undefined undefined
Trial Locations
- Locations (1)
Hospital Luis Sanchez Bulnes
🇲🇽Mexico city, DF, Mexico